Skip to main content

Together we are beating cancer

Donate now

Cancer News

For Researchers

Showing 12 out of 386 results

This episode features outgoing CRUK Chief Scientist, Professor Karen Vousden. Known for her work on the tumour suppressor protein, p53, she has also worked on HPV and cancer metabolism. She talks about the success and challenges of work around p53, her joy at being involved in the early work around HPV, the frustrations of coming so close to a huge breakthrough and how life as a researcher has changed. This episode features outgoing CRUK Chief Scientist, Professor Karen Vousden. Known for her work on the tumour suppressor protein, p53, she has also worked on HPV and cancer metabolism. She talks about the success and challenges of work around p53, her joy at being involved in the early work around HPV, the frustrations of coming so close to a huge breakthrough and how life as a researcher has changed.

by Phil Prime | Podcast | 25 August 2022

25 August 2022

This entry is part 5 of 9 in the series Cancer Research Matters - series 1
%postcontent%

We catch up with Dr Alexis Webb and find out about the upcoming Early Detection of Cancer Conference, the importance of collaboration and why these are exciting times for the field... We catch up with Dr Alexis Webb and find out about the upcoming Early Detection of Cancer Conference, the importance of collaboration and why these are exciting times for the field...

by Phil Prime | Interview | 18 August 2022

18 August 2022

CRISPR-Cas9 is a world-renowned genome editing tool, but much of the hype has been focused on direct clinical applications. However, there is clear potential for utilising the system in functional genomic screens to develop new cancer medicines... CRISPR-Cas9 is a world-renowned genome editing tool, but much of the hype has been focused on direct clinical applications. However, there is clear potential for utilising the system in functional genomic screens to develop new cancer medicines...

by Cancer Research UK | In depth | 16 August 2022

16 August 2022

Our policy department give us an update on the current state of play on post-Brexit science funding, what you can do to help and what we know about the Government’s ‘Plan B’… Our policy department give us an update on the current state of play on post-Brexit science funding, what you can do to help and what we know about the Government’s ‘Plan B’…

by Phil Prime | Analysis | 25 July 2022

25 July 2022

This entry is part 3 of 10 in the series Diversity in research
%postcontent%

This episode features CRUK Chairman, Professor Sir Leszek Borysiewicz. Following a distinguished academic and clinical research career, Leszek’s roles have included Chief Executive of the Medical Research Council and Vice Chancellor of the University of Cambridge. He talks about the development of the HPV vaccine, the difficulties of navigating a research career and why we must start to embrace failure… even a negative result, he says, is positive. This episode features CRUK Chairman, Professor Sir Leszek Borysiewicz. Following a distinguished academic and clinical research career, Leszek’s roles have included Chief Executive of the Medical Research Council and Vice Chancellor of the University of Cambridge. He talks about the development of the HPV vaccine, the difficulties of navigating a research career and why we must start to embrace failure… even a negative result, he says, is positive.

by Phil Prime | Podcast | 20 July 2022

20 July 2022

This entry is part 4 of 9 in the series Cancer Research Matters - series 1
%postcontent%

We recently welcomed some early career researchers to observe some of the panel discussions and interviews for our Research Careers Committee. So, how did they get on? We recently welcomed some early career researchers to observe some of the panel discussions and interviews for our Research Careers Committee. So, how did they get on?

by Phil Prime | In depth | 6 July 2022

6 July 2022

New research suggests that last year, cancer research investment generated over £5bn in economic benefits to the UK, with CRUK supporting over 9,000 full-time jobs. New research suggests that last year, cancer research investment generated over £5bn in economic benefits to the UK, with CRUK supporting over 9,000 full-time jobs.

by Cancer Research UK | Analysis | 1 July 2022

1 July 2022

Nobody fully understands why people go off food in response to infection, early pregnancy and some chemotherapies for cancer. A flurry of research published in recent years has narrowed down the search for the culprit mechanism, and Cancer Research UK-funded researchers have just found another piece of the puzzle. Nobody fully understands why people go off food in response to infection, early pregnancy and some chemotherapies for cancer. A flurry of research published in recent years has narrowed down the search for the culprit mechanism, and Cancer Research UK-funded researchers have just found another piece of the puzzle.

by Phil Prime | In depth | 15 June 2022

15 June 2022

This episode features Professor Sara Zanivan. She talks about how understanding the tumour microenvironment has developed over the past 20 years, how the techniques of proteomics have really freed researchers to ask the important questions and why we could even see mass-spec proteomics in the clinic. This episode features Professor Sara Zanivan. She talks about how understanding the tumour microenvironment has developed over the past 20 years, how the techniques of proteomics have really freed researchers to ask the important questions and why we could even see mass-spec proteomics in the clinic.

by Phil Prime | Podcast | 23 May 2022

23 May 2022

This entry is part 3 of 9 in the series Cancer Research Matters - series 1
%postcontent%